Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A lab-on-a-chip device for measuring multiple biochemical and biophysical biomarkers of Alzheimer’s disease

Award Number: R21AG085089
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2024
PERIOD OF PERFORMANCE END DATE: 04/30/2027

Group Awards By:

View Award Description

A lab-on-a-chip device for measuring multiple biochemical and biophysical biomarkers of Alzheimer’s disease - PROJECT SUMMARY Alzheimer’s disease (AD) is the most common form of dementia, causing 50–75% of all dementia cases, and currently affecting approximately 50 million people worldwide. A major problem in AD research is that we still do not have accepted measures of biomarkers that are useful in clinical trials for AD, which makes it difficult to enroll the most relevant cohorts and test the mechanism of action of drug candidates. This is compounded by the fact that current biomarker testing is dominated by cerebrospinal fluid (CSF) analysis and positron emission tomography (PET) scans. CSF testing is invasive, while PET scans are expensive and not easily accessible. Research on alternative drug targets for AD has recently started to grow, and as a result, there is a strong need for new biomarker targets and new modalities to measure these biomarkers. These modalities would be ideally low-cost, non-invasive, and easily scalable. Raman spectroscopy has shown good promise in distinguishing early-stage AD from cognitively healthy controls, while mass spectrometry has shown good potential in distinguishing certain neurological disorders from cognitively healthy controls using the novel concept of conformational biomarkers. Different from classical concentration-based disease biomarkers, conformational biomarkers reflect the changes in structure. However, conventional Raman spectroscopy systems are not scalable, and mass spectrometry is both expensive and time consuming. An emerging concept is waveguide enhanced Raman spectroscopy (WERS). Along with providing increased light efficiencies, it can also make use of current CMOS fabrication techniques, allowing nanophotonic chips to be mass produced. In terms of conformational sensing, light scattering spectroscopy has been demonstrated as a reliable technique for sensing nanoscale changes in conformational properties. Given these findings, we hypothesize that a scalable photonics-based lab-on-a-chip device can be used for the simultaneous investigation of multiple novel biochemical and biophysical AD biomarkers. These hypotheses will be addressed in the experiments of the following Specific Aims: (1) Develop a low-cost, scalable, and label- free testing platform based on waveguide enhanced Raman spectroscopy to detect existing and novel biomarkers in blood plasma; and (2) Develop a prototype label-free testing platform based on light scattering spectroscopy for characterizing misfolded proteins in CSF samples. Should these aims be successful, it opens the possibility of developing a scalable lab-on-a-chip device for straightforward screening of AD patients and monitoring of disease progression, both of which are critical requirements for future AD therapeutic development. The results would also have broad implications for other neurological disorders.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $216,125 )
2026	2026	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	000	3	3/26/2026	NON-COMPETING CONTINUATION	$216,125
														Subtotal = $216,125

Issue Date FY: 2025 ( Subtotal = $216,125 )
2025	2025	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	001	2	4/28/2025	NON-COMPETING CONTINUATION	$21,612
2025	2025	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	000	2	4/1/2025	NON-COMPETING CONTINUATION	$194,513
														Subtotal = $216,125

Issue Date FY: 2024 ( Subtotal = $236,022 )
2024	2024	BETH ISRAEL DEACONESS MEDICAL CENTER, INC.	330 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Aging Research	000	1	4/29/2024	NEW	$236,022
														Subtotal = $236,022

Grand Total All Awards = $668,272

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A lab-on-a-chip device for measuring multiple biochemical and biophysical biomarkers of Alzheimer’s disease

Award Number: R21AG085089

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2024

PERIOD OF PERFORMANCE END DATE: 04/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer